Cash-Strapped Biohaven Sells Its Lead Epilepsy Drug to SK for Up to $795M

Biohaven is selling rights to its most advanced experimental medicine — the focal epilepsy drug Opakalim — to South Korea’s SK Biopharmaceuticals in a deal worth up to $795 million, driven by the biotech’s need for cash.

The deal structure

$350 million upfront, $50 million in 2027, up to $150 million in development and regulatory milestones, up to $245 million in obligations transferred from a previous owner (Knopp Biosciences), and mid-teens to low-twenties royalties if approved.

Two features stand out. The $350 million upfront is a large share of the headline figure, unusual for a licensing deal and a sign this is a sale driven by the seller’s need rather than a partnership. And the $245 million in transferred obligations is not money Biohaven receives — it is liability SK assumes, inherited from when Biohaven acquired the asset. Removing that from the balance sheet is itself part of the value.

Why Biohaven sold

The company faced “a dwindling bank account after a series of research setbacks,” including failures in depression, rare disease and spinal muscular atrophy programmes, and needed non-dilutive financing.

That term is doing significant work. A biotech needing cash has essentially three options. It can issue shares, which dilutes existing holders and is punishing when the share price has already fallen — raising a given sum requires selling more of the company. It can borrow, which requires either assets or predictable revenue, neither of which a clinical-stage biotech has. Or it can sell an asset.

After a run of failures the first option becomes prohibitively expensive precisely when cash is most needed. Selling a programme converts a future possibility into immediate certainty, at a discount.

The timing is what makes this notable

Opakalim’s pivotal Rise3 trial results are expected before year-end.

Selling the most mature asset months before its defining readout is a genuinely striking decision. If Rise3 succeeds, SK owns an approvable epilepsy drug bought at pre-readout prices, and Biohaven retains only royalties. If it fails, Biohaven made an excellent trade.

One analyst called it “a fairly surprising deal.” The interpretation depends on what Biohaven knows — and companies generally have blinded data at this stage, so the more likely explanation is simply that the runway would not stretch to the readout. A company that cannot afford to wait does not get to wait for good news.

CEO Vlad Coric said the deal provides capital “while preserving substantial long-term upside” — which the royalty structure genuinely does, though at a fraction of ownership.

What SK is buying

Beyond one drug, SK gains a Kv7 ion-channel platform.

Kv7 potassium channels help regulate neuronal excitability — they act as a brake on how readily neurons fire. Opening them raises the threshold for the runaway synchronised firing that constitutes a seizure, which makes the target mechanistically well matched to epilepsy.

The class has a complicated history. An earlier Kv7 opener reached the market and was withdrawn after prolonged use produced blue-grey skin and retinal pigmentation, an unusual and disqualifying effect. That episode both validated the target clinically and left developers needing to demonstrate their compound does not repeat it — which is part of what Rise3 is establishing.

SK Biopharmaceuticals is a logical buyer, having built commercial epilepsy capability of its own.

Why focal epilepsy is worth pursuing

Despite many available antiseizure medications, roughly a third of people with epilepsy have seizures that are not controlled by drugs. That fraction has proven stubborn, and adding another agent with a familiar mechanism rarely helps — which is why a differentiated mechanism matters more than another entrant.

Uncontrolled seizures carry consequences beyond the events themselves: driving restrictions, employment limits, injury risk and elevated mortality.

What this says about the sector

The deal is a window into how cash pressure reshapes biotech dealmaking. In a favourable financing environment, Biohaven would have raised equity and held the asset through readout, capturing the full value of success.

In a constrained one, even a company’s best programme becomes a financing lever. Assets get sold not because the seller values them least but because they are the only thing liquid enough to sell — which systematically transfers upside from developers to acquirers with capital.

What to watch

Rise3 before year-end settles who got the better of it. A positive readout makes this look like a distressed sale of a valuable asset; a negative one makes it look like excellent timing.

What royalties are actually worth

The phrase “preserving substantial long-term upside” deserves examination, because royalty retention is the standard consolation in deals like this and its value varies enormously.

Mid-teens to low-twenties percentages are genuinely favourable rates by industry standards, and on a successful epilepsy drug they could eventually exceed the upfront payment. But royalties arrive only after approval and commercial launch, which is years away even if Rise3 succeeds, and they depend entirely on how well the acquirer commercialises — a variable the seller no longer controls.

The structural asymmetry is that a company selling because it needs cash now is trading a certain payment today for uncertain payments in a future it may not reach. Royalty streams are also frequently sold on again to specialist financing firms at a discount when the next funding gap arrives, which converts the retained upside into another upfront payment at a further markdown.

Either way, Biohaven has bought itself the runway to find out. Business news, not investment advice.